GeneOne Life Science, Inc.
Financials
Valuation Metrics
GeneOne Life Science, Inc.'s Market Cap is ₩485B. At end of 2025 it was ₩1780B. Ranked #1761 of 2,436 in KR market (top 72%), #696 of 787 on KOSPI (top 88%), #192 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 82%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 48.53B KRW | KR#1,761/2,436 Sec#192/234 |
| Revenue | 17.12B KRW | KR#2,176/2,436 Sec#161/234 |
| Net Income | -45.40B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 131.29B KRW | KR#1,560/2,436 Sec#124/234 |
| Net Assets | 51.15B KRW | KR#1,859/2,436 Sec#160/234 |
| Employees | 44 | KR#2,074/2,436 Sec#187/234 |
| Value | ||
| P/B | 0.95x | KR#1,444/2,436 Sec#91/234 |
| P/S | 2.83x | KR#1,991/2,436 Sec#123/234 |
| FCF Yield | -34.13% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -88.74% | KR#2,332/2,436 Sec#217/234 |
| ROA | -34.58% | KR#2,326/2,436 Sec#210/234 |
| Op. Margin | -217.93% | KR#2,341/2,436 Sec#187/234 |
| Revenue Growth | -69.65% | KR#2,326/2,436 Sec#207/234 |
| Financial Health | ||
| Debt Ratio | 256.65% | KR#2,013/2,436 Sec#212/234 |
| Total Debt | 30.50B KRW | KR#1,186/2,436 Sec#92/234 |
| FCF | -16.56B KRW | KR#1,854/2,436 Sec#173/234 |
| Cash | 5.30B KRW | KR#1,966/2,436 Sec#175/234 |
| Current Ratio | 0.46x | KR#2,274/2,436 Sec#221/234 |
| Performance | ||
| 1Y Return | -76.53% | KR#2,389/2,436 Sec#231/234 |
| 1M Return | 0.00% | KR#874/2,436 Sec#77/234 |
| From 52W High | -80.11% | KR#2,350/2,436 Sec#219/234 |
| 1Y MDD | -79.62% | KR#2,289/2,436 Sec#211/234 |
| Trading | ||
| Foreign Own. | 1.53% | KR#1,124/2,436 Sec#110/234 |
| Per Share | ||
| EPS | -2,666 KRW | KR—/2,436 Sec—/234 |
| BPS | 2,847 KRW | KR#1,845/2,436 Sec#144/234 |
Company Info
Geneone Lifescience, established in 1976 for the manufacturing and sales of apparel interlining, was listed on the stock market in 1987 and operates local subsidiaries in the United States and Vietnam. The company is developing biopharmaceutical CDMO business and new biopharmaceutical drugs, with a focus on SFTS and COVID-19 DNA vaccines, and novel anti-inflammatory therapeutics. Leveraging its nucleic acid-based vaccine platform technology, it received invitations to the World Vaccine Congress Asia in 2023 and 2024, and was awarded the Grand Prize in Korea's promising vaccine sector. Geneone Lifescience is headquartered in Yeongdeungpo-gu, Seoul Metropolitan City.